Retatrutide explained: The next big GLP-1? скачать в хорошем качестве

Retatrutide explained: The next big GLP-1?

📩 Email: [email protected] We’re seeing new GLP-1 medications pop up constantly, and retatrutide stands out because it targets three receptors at once (GLP-1 + GIP + glucagon). It’s a once-weekly injection that’s not approved yet, but early trials are promising. In this video, I break down how it works, what the Phase 2 trials found (including waist changes), and what other trials are in the pipeline. Links to research: Phase two trial https://www.nejm.org/doi/full/10.1056... 💬 Have questions? Drop them in the comments—I’d love to hear your thoughts. A little bit about me: My name is Kamini. I have a Bachelor of Pharmacy with First Class Honours from Curtin University and I’m currently working as a registered pharmacist while completing my Master of Human Nutrition. As I learn through my work and studies, I enjoy sharing that knowledge here so we can all play the long game that is health, together. Some words: Retatrutide, triple agonist, GLP-1 GIP glucagon, next gen GLP-1, Mounjaro, Zepbound, tirzepatide, semaglutide, Wegovy, Ozempic, obesity treatment, weight loss medication, type 2 diabetes